SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert, J., Wetzel, M.C., Bartle, L.M., Skaletskaya, A., Goldmacher, V.S., Vallee, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., Dumontet, C., Plesa, A., Chiron, M., Lejeune, P., Chittenden, T., Park, P.U., Blanc, V.(2014) Clin Cancer Res 20: 4574-4583
- PubMed: 24987056 
- DOI: https://doi.org/10.1158/1078-0432.CCR-14-0695
- Primary Citation of Related Structures:  
4CMH - PubMed Abstract: 
The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984.
Organizational Affiliation: 
Research and Development, ImmunoGen, Inc., Waltham, Massachusetts. jutta.deckert@immunogen.com.